Cresset Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.41M Buy
108,452
+22,389
+26% +$661K 0.01% 507
2026
Q1
$2.13M Buy
86,063
+2,094
+2% +$49.9K 0.01% 545
2025
Q4
$1.96M Buy
83,969
+163
+0.2% +$3.63K 0.01% 574
2025
Q3
$1.65M Buy
83,806
+4,349
+5% +$89.4K 0.01% 599
2025
Q2
$1.72M Buy
79,457
+66,752
+525% +$1.58M 0.01% 534
2025
Q1
$308K Buy
+12,705
New +$286K ﹤0.01% 1300

Other funds holding CPRX

Cresset Asset Management's CPRX Position: Q2 2026 in Review

Cresset Asset Management increased its Catalyst Pharmaceutical (CPRX) stake by 26% in Q2 2026, buying an estimated $661K and bringing the position to 108,452 shares worth $3.41M. The position accounts for 0.01% of the portfolio, ranked #507.

Cresset Asset Management first reported a position in CPRX in Q1 2025 and has held it in 6 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Cresset Asset Management held 108,452 shares of Catalyst Pharmaceutical worth $3.41M as of Q2 2026.
  • Cresset Asset Management bought 22,389 Catalyst Pharmaceutical shares in Q2 2026, an estimated $661K.
  • Catalyst Pharmaceutical made up 0.01% of Cresset Asset Management's portfolio in Q2 2026, its #507 holding.
  • Cresset Asset Management first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.